RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Nine Months ended December 31, 2011
Currency: Indian Rupees (INR) with U.S. Dollar (USD) convenience translation (Rate: 53.01 INR/USD)
Business Overview: DRL is a leading India-based pharmaceutical company operating in three primary segments: Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The company manufactures and markets generic drugs, active ingredients, and proprietary products globally, with significant operations in India, North America, Russia, and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenues increased by 29% to INR 70,153 million for the nine months ended Dec 31, 2011, compared to INR 54,520 million in the prior year. The Global Generics segment drove this growth with a 32% increase, primarily due to North America and Russia.
• Profitability Surge: Net profit increased by 41% to INR 10,835 million. Operating profit rose by 60% to INR 14,081 million.
• North America Expansion: Revenues from North America in the Global Generics segment grew 77% year-over-year, largely attributable to the launch of Olanzapine (generic Zyprexa) with 180-day marketing exclusivity and other new product launches.
• Margin Improvement: Gross margin improved from 54% to 56%, aided by the launch of high-margin products and favorable currency impacts, partially offset by a shift in product mix.
• Debt Structure: The company significantly increased long-term borrowings, securing a new INR 10,713 million loan from a Swiss subsidiary to finance long-term needs, while short-term borrowings also increased to support working capital.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

• Product Pipeline: Management expects to launch several key products in the next six months in North America. The company has 79 ANDAs pending FDA approval, including 41 Paragraph IV filings.
• Strategic Partnerships: Signed a Memorandum of Understanding with FUJIFILM Corporation to establish a joint venture in Japan for generic drugs.
• Recent Launches: Launched Ziprasidone Hydrochloride capsules in the U.S. in March 2012 (subsequent to period end).

Risks and Contingencies

• Regulatory Actions (FDA): The U.S. FDA issued a warning letter and an Import Alert (Detention without Physical Examination) for the company's Mexico facility in June 2011 regarding API and steroid manufacturing. While management believes the impact is not material to the overall business, exports of affected products to the U.S. are restricted until compliance is verified.
• Patent Litigation:
  • Fexofenadine (Allegra): Ongoing litigation with Sanofi-Aventis and AMR in the U.S. regarding patent infringement. A preliminary injunction was dissolved in Jan 2011, but sales remain at risk pending final resolution.
  • Olanzapine (Zyprexa): Litigation in Canada regarding patent validity. The company is exposed to potential damages equal to its profit share if Eli Lilly prevails in its appeal.
• Environmental and Tax: Pending environmental litigation in India regarding pollution compensation and indirect tax disputes in India. The company believes these will not have a material adverse effect.
• Policy Changes:
  • India: A draft National Pharmaceutical Pricing Policy 2011 proposes expanding price controls to 60% of the market, which could impact margins.
  • Russia: New federal laws restrict interactions between medical practitioners and pharmaceutical companies, potentially affecting sales strategies.

Unusual Items

• Foreign Exchange: Significant net foreign exchange gains (INR 593 million for nine months) contributed to finance income, driven by the depreciation of the Indian Rupee against multiple currencies.
• Acquisition: Completed the acquisition of GSK's manufacturing facility and product rights in Tennessee, U.S., in March 2011 for INR 1,169 million, recognized as a business combination.

Investor Verification Checklist

• FDA Compliance Status: Verify the current status of the Import Alert (DWPE) on the Mexico facility and the timeline for lifting the restriction on API exports to the U.S.
• Patent Litigation Outcomes: Monitor the final rulings in the Fexofenadine (U.S.) and Olanzapine (Canada) cases, as adverse judgments could result in significant damages or market exclusions.
• Working Capital Trends: Review the Days Sales Outstanding (DSO), which increased to 88 days from 68 days, driven by new product launches in North America with longer credit terms.
• Debt Covenants: Confirm compliance with financial covenants on the new INR 10.7 billion Swiss subsidiary loan (e.g., Net Financial Indebtedness to EBITDA ratio not exceeding 2.3:1).
• Regulatory Policy Impact: Assess the final impact of India's new National Pharmaceutical Pricing Policy on the company's domestic formulation margins.